9:15 am Chair’s Opening Remarks
Developing Next Generation Multispecifics for a Flourishing Future
9:20 am Uncovering the Therapeutic Potential of a Next Generation Tumor Treg Deplete
Synopsis
- Uncovering INV322 as a next-generation bispecific Treg depleter that uses Invenra’s SNIPER B-Body® Technology
- Capitalizing on avidity to deplete Tregs specifically in the tumor microenvironment by blocking both its targets and eliciting ADCC
- Preclinical data supportive of INV322’s therapeutic potential will be shown. IND-enabling
activities are underway
9:50 am Session Reserved for Gem Pharmatech
Synopsis
10:00 am Guided Antibody Tumor Engagers (TwoGATE™), a Sophisticated & Differentiated Approach for T Cell Redirection in Solid Tumors
Synopsis
- Revolutionizing cancer treatment by harnessing the immune system. However, on-target off-tumor toxicities including Cytokine Release Syndrome limit their therapeutic potential
- Developing TwoGATE™ is the split anti-CD3 paratope that enables a true dual Ag “AND” gate by targeting each inactive half-paratope to a different antigen on the same tumor cell for reassembly of the CD3 binding complex only on the tumor cell surface
- Engineering, developability, in vitro and in vivo potency and NHP tolerability data as well as our thoughts on ways to overcome the barriers to successful T cell redirection in solid tumors will be discussed
10:30 am
Morning Break & Networking
Target Discovery, Mechanistic Diversity & Translational Science
Translational Science
11:00 am Translational PK/PD Investigations & Multiscale Mechanism-Based Modeling to Support Development of T Cell Redirecting Antibodies
Synopsis
- Understanding unique features and prevailing challenges associated with I/O therapies
- How mechanistic PK/PD model can help with the forward and reverse translation
- Comprehending the utility of receptor occupancy and immune synapse in establishing a robust translational PK/ PD model for T-cell redirecting antibodies
11:30 am PreTarg-it®: A modular platform utilizing bispecific antibodies for optimized biodelivery of payloads.
Synopsis
- Generating novel and highly potent bispecific antibody modalities to treat underserved patient populations living with solid cancers
- Preclinical proof-of-concept has been achieved for oxMIF-specific pre-targeted radioimmunotherapy, using OncoOne’s proprietary PreTarg-it® platform.
- This approach provides higher tumor to non-tumor ratios and improved therapeutic indexes than traditional approaches.
12:00 pm Session Reserved for Asimov
Synopsis
Novel Formats, Product Design & Manufacturability
Manufacturability
11:00 am Session Reserved for Carterra
Synopsis
11:30 am Potency Assay Strategy from Early to Late Clinical Development: A Bispecifics Case Study
Synopsis
- Defining appropriate release and stability approach for biological activity for IND filing
• Correlation of surrogate potency assay to mechanism of action
12:00 pm Session Reserved for Applied BioMath
Synopsis
12:30 pm
Lunch & Networking
Solid Tumor Engagers
1:30 pm Decoupling Cytotoxicity with Cytokine Release: Development of Safe CD3 T Cell Engagers for Solid Tumors
Synopsis
- Discovery and design of low affinity CD3 T cell engagers to set new standards for IO
- Utilizing the affinity and avidity effect to selectively target FOLR1high ovarian cancer
- Pre-clinical development of AMG-340, a PSMAxCD3 BiTE for mCRPC
2:00 pm Overcoming the Challenges of a First-Generation CD123-Directed Bispecific CD3-Engaging DART Molecule
Synopsis
- Experience with the first-generation CD123 x CD3 DART molecule, flotetuzumab
- Molecular engineering to uncouple cytolysis from cytokine release
- Combinatorial approaches with standard-of-care agents
2:30 pm Generation of Innovative B7H4 x CD3 & B7H4 x 4-1BB Bispecifics for Solid Tumor Therapies
Synopsis
- Generation of innovative B7H4 x CD3 and B7H4 x 4-1BB bispecifics by using HBICE® bispecific platform
- B7H4 x CD3 shows promising anti-tumor efficacy with limited cytokines release
- B7H4 x 4-1BB further enhances B7H4 x CD3 efficacy, especially at low E:T ratio. It suggests combination of B7H4 x CD3 and B7H4 x 4-1BB therapy will provide new opportunities for solid tumor treatment
Data & AI
1:30 pm Graphical Design, Engineering & In Silico Cloning of Multispecific Antibodies
Synopsis
- Designing and engineering proteins on a graphical user interface that also takes care of plasmid generation
- Design and analyze molecules simultaneously
- Turning protein design into a fun activity
2:00 pm TREAT 2.0: A Versatile Platform Technology for Development of Multispecific Antibodies
Synopsis
- Unlocking new biology with TREAT 2.0 platform technology
- Addressing the design and developability profiling by utilizing TREAT 2.0
- Optimizing structure-activity relationships through epitope and affinity adjustments
2:30 pm Leveraging Homotypic Antibody Interfaces for Biotherapeutic Engineering
Synopsis
- A homotypic interaction encoded by germline CDRL2 sequences enhances TNFRSF agonists
- Engineering of a homotypic interface between heavy chain variable regions for heterodimeric receptor agonism
- Novel antibody interfaces revealed through structural mining
3:00 pm
Afternoon Break & Networking
Multispecifics in Clinical Use & Combinational Mechanisms
3:30 pm Improving Bispecific Antibody Outcome in Acute Myeloid Leukemia
Synopsis
- Bite and CAR T cell therapy is still in early phases of development compared to other diseases
- Ideal target still to be found
- Need to overcome immunosuppressive environment
4:00 pm Panel Discussion – Unlocking the Potential of Combinatorial Strategies of Bispecifics in a Clinical Setting
Synopsis
- Specifically focusing on co-stimulation approaches and combinational efforts with other standards of care
- Exploring the current, pre-clinical view and how this impacts early clinical trials